Delving into the Latest Updates on Nanocurcumin(Tehran University of Medical Sciences) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Mechanism-

Therapeutic Areas

NeoplasmsImmune System DiseasesSkin and Musculoskeletal Diseases

Active Indication

NeoplasmsRheumatoid ArthritisSolid tumor

Inactive Indication-

Originator Organization

Tehran University of Medical Sciences

Active Organization

JYANT Technologies, Inc.

Tehran University of Medical Sciences

Inactive Organization-

Drug Highest PhaseClinical

First Approval Date-

Regulation-

BACKGROUNDBiofilms are a potential harbor for many microorganisms. The aim of this study was to test the efficacy of riboflavin (Rib), nano-micelle curcumin (NC), and hydrogen peroxide (HP), alone and in combination with the respective light (light-emitting diode (LED) or 980 nm diode laser) on the reduction of Streptococcus mutans and Lactobacillus acidophilus dual-species biofilms and their effect on the enamel mineral loss.MATERIALS AND METHODSThe biofilms were formed on saliva-coated enamel slabs. Then, the biofilms were treated with antimicrobial photodynamic therapy (PDT) based on LED, Rib, and NC photosensitizers and with HP also based on a 980 nm diode laser (n = 8 per group). A crystal violet assay was performed to determine the reduction of the dual-species biofilms. The enamel slabs were analyzed for calcium and phosphorus content by scanning electron microscopy (SEM) and energy dispersive X-ray spectroscopy (EDX).RESULTSWhile HP-PDT showed a reduction of 37% (p < 0.001), PDT with NC resulted in an even greater reduction of dual-species biofilms (40%, p < 0.001) than HP- and Rib-mediated PDT. In the EDX test, no significant difference was found between the control group and the treatment groups.CONCLUSIONSThe use of natural photosensitizers such as NC in PDT has an effect that may be potentially important in reducing caries-causing bacteria.

01 Dec 2024·Phytomedicine

Effects of metformin and curcumin in women with polycystic ovary syndrome: A factorial clinical trial

Article

Author: Feghhi, Fatemeh ; Sheervalilou, Roghayeh ; Ghaznavi, Habib ; Sepidarkish, Mahdi ; Razavi, Maryam

BACKGROUNDPolycystic ovary syndrome (PCOS) is a common endocrine disorder in women, associated with dyslipidemia, insulin resistance, and hormonal imbalances. Metformin and curcumin have shown promise in improving these metabolic and hormonal parameters individually, but their combined effects in PCOS remain unclear.METHODSWe conducted a randomized, double-blind, placebo-controlled, 12-week factorial trial involving 200 women with PCOS. Participants were randomly assigned in a 1:1:1:1 ratio to receive metformin (500-mg/8 h) + placebo, nanocurcumin soft gel capsule (80-mg/8 h) + placebo, metformin (500-mg/8 h) + nanocurcumin (80-mg/8 h), or double placebo. Lipid profiles, glucose metabolism markers, hormonal parameters, body weight, and body mass index (BMI) were assessed at baseline and week 12.RESULTSThe combination of metformin and curcumin demonstrated significant improvements in lipid profiles, glucose metabolism, hormonal parameters, body weight, and BMI compared to individual agents or placebo. Greater reductions in low-density lipoproteins (LDL) cholesterol, total cholesterol (TC), and triglyceride (TG) levels were observed with the combination therapy, along with increased high-density lipoproteins (HDL) cholesterol. Additionally, the combination therapy significantly improved markers of glucose metabolism and showed synergistic effects in reducing body weight and BMI. Reductions in testosterone and improvements in Follicle-stimulating hormone (FSH) and Luteinizing hormone (LH) levels were also observed with combination therapy.CONCLUSIONThe combination of metformin and curcumin demonstrates superior efficacy in improving lipid profiles, glucose metabolism, hormonal parameters, body weight, and BMI in women with PCOS compared to individual agents or placebo. This highlights the potential synergistic effects of combining these agents for the management of PCOS.

01 Nov 2024·Journal of Cellular Physiology

RETRACTION: Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID‐19 patients

RETRACTION: S. Tahmasebi, M. A. El‐Esawi, Z. H. Mahmoud, A. Timoshin, H. Valizadeh, L. Roshangar, M. Varshoch, A. Vaez, S. Aslani, J. G. Navashenaq, L. Aghebati‐Maleki, M. Ahmadi, “Immunomodulatory Effects of Nanocurcumin on Th17 Cell Responses in Mild and Severe COVID‐19 Patients,” Journal of Cellular Physiology 236, no. 7 (2021): 5325‐5338, https://doi-org.libproxy1.nus.edu.sg/10.1002/jcp.30233.The above article, published online on 28 December 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor‐in‐Chief, Alexander Hutchison; and Wiley Periodicals LLC.The decision to retract this article follows concerns raised by third parties over the legitimacy of authorship positions. Some listed authors, lacking prior collaboration history with the submitting author group, were added at later stages of the revision process. Subsequent investigation by the publisher has revealed that the article has been published solely on the basis of a compromised peer review process. The retraction is warranted due to the compromised integrity of the article's peer review and the concerns over authorship positions. The corresponding author M. Ahmadi, the first author S. Tahmasebi, and co‐authors H. Valizadeh, L. Roshangar and L. Aghebati‐Maleki disagree with the decision of retraction. Final confirmation could not be obtained by the remaining co‐authors.

100 Deals associated with Nanocurcumin(Tehran University of Medical Sciences)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rheumatoid Arthritis	Preclinical	US	JYANT Technologies, Inc.	30 Jan 2022
Solid tumor	Preclinical	US	JYANT Technologies, Inc.	30 Jan 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2022	Not Applicable	Thyroid Cancer	90	40 mg nano-curcumin	(fgrkqlgwpl) = lunvboqemr jmofkkgada (edxtpgnpbf, 0.58) View more	Positive	08 Aug 2022
				80 mg nano-curcumin	(fgrkqlgwpl) = uctnpkvgfs jmofkkgada (edxtpgnpbf, 0.85) View more